www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

US EUROPE AFRICA ASIA 中文
Business / Companies

Bayer plans to focus entirely on Life Science businesses

(chinadaily.com.cn) Updated: 2014-09-19 18:07

Bayer intends in the future to focus entirely on the Life Science businesses – HealthCare and CropScience – and float MaterialScience on the stock market as a separate company. In this way Bayer is positioning itself as a world-leading company in the field of human, animal and plant health. The Supervisory Board unanimously approved the Board of Management's plans Thursday. "Our intention is to create two top global corporations: Bayer as a world-class innovation company in the Life Science businesses, and MaterialScience as a leading player in polymers," Bayer CEO Dr. MarijnDekkers announced. He said both companies have excellent prospects for success in their respective industries. Employment levels are expected to remain stable over the next few years, both globally and in Germany.

MaterialScience to gain direct access to the capital market

In recent years, Bayer's center of gravity has greatly shifted toward its Life Science activities with the successful launch of novel pharmaceutical products, the pending acquisition of the over-the-counter products business of Merck & Co Inc, United States, and the very successful development of the CropScience business.

The aim is to continue the positive development of these activities in the future through further investment in growth. Following its regular evaluation of the business portfolio, the Board of Management has therefore decided to focus the company on these areas. The Life Sciences currently already account for about 70 percent of Bayer's sales and 88 percent of EBITDA before special items.

It is planned to float the MaterialScience business on the stock market as a separate company within the next 12 to 18 months. A major reason for this move is to give MaterialScience direct access to capital for its future development. This access can no longer be adequately ensured within the Bayer Group due to the substantial investment needs of the Life Science businesses for both organic and external growth. Also, as a separate company, MaterialScience can align its organizational and process structures and corporate culture entirely toward its own industrial environment and business model.

Bayer plans to focus entirely on Life Science businesses
Agro-project aims for sustainable, efficient farming
Bayer plans to focus entirely on Life Science businesses
Bayer HealthCare to expand production capacity

Bayer to retain a balanced portfolio

The companies of the future Bayer Group had pro forma sales of approximate 29 billion euros ($37.3 billion) in 2013. They will employ nearly 99,000 people, including about 29,500 in Germany. Corporate headquarters will remain in Leverkusen.

"Bayer will continue as an enterprise with an attractive and balanced portfolio and a primary focus on organic growth,"Dekkers explained. To this end, the company intends to raise its research and development spending, selectively strengthen early research at the interface between HealthCare and CropScience, and continue driving the successful commercialization of the recently launched pharmaceutical products. Bayer expects these products – the anticoagulant Xarelto?, the eye medicine Eylea?, the cancer drugs Stivarga? and Xofigo?, and the pulmonary hypertension drug Adempas? – to have a combined peak annual sales potential of at least 7.5 billion euros.

Separate MaterialScience business more flexible in the face of global competition

"We firmly believe that MaterialScience will use its separate status to deploy its existing strength even more rapidly, effectively and flexibly in the global competitive arena,"Dekkers commented. A strategy and corporate culture aligned to technological and cost leadership, coupled with the ability to make its own investment and portfolio decisions, would give MaterialScience the best development prospects in a highly competitive market. That, said Dekkers, includes direct capital market access so that it would not have to compete with the Life Science businesses for investment funding in the future.

"MaterialScience is a very well positioned business that today operates very modern, competitive, large-scale facilities. We have steadily invested in these facilities, even in difficult economic times,"Dekkers pointed out, citing the world-scale production facilities in Shanghai, China, and the new TDI plant in Dormagen, Germany, which is to be officially inaugurated in December. Between 2009 and 2013 alone, Bayer invested a total of over 3.8 billion euros in property, plant and equipment and research and development for the MaterialScience business.

Following the intended flotation, MaterialScience will be Europe's fourth-largest chemical company; it had global sales in 2013 of more than 11 billion euros (pro forma figure). The new company is planned to have a global workforce of roughly 16,800, including about 6,500 in Germany.It will have a new name and a separate identity and be headquartered in Leverkusen.

Hot Topics

Editor's Picks
...
...
主站蜘蛛池模板: 精品国产免费一区二区三区 | 国产欧美日韩图片一区二区 | 久久aa毛片免费播放嗯啊 | 国产亚洲精品成人一区看片 | 日本一区三区二区三区四区 | 欧美特黄三级成人 | 毛茸茸年轻成熟亚洲人 | 国产一级一国产一级毛片 | 国产欧美日韩视频在线观看 | 亚洲色色色图 | 久久频这里精品99香蕉久网址 | 久草资源网站 | 在线a人片免费观看国产 | 国产一级做a爰片久久毛片99 | 一级日韩| 日本三级香港三级三级人 | 国产一级在线现免费观看 | 国产91精品一区 | 日本道色 | 日本高清aⅴ毛片免费 | 毛片在线看免费 | 免费视频网站一级人爱视频 | 日本黄网站高清色大全 | 成人综合网址 | 亚洲三级毛片 | 高清国产在线播放成人 | 成 人 黄 色 免费播放 | 91无套极品外围在线播放 | 国产图片亚洲精品一区 | 久久九九爱 | 亚洲第一视频在线观看 | 日韩一级在线视频 | 亚洲综合久久久久久中文字幕 | 一级特黄特黄毛片欧美的 | 一区二区三区欧美在线 | 欧美aaaaaa| 国产精品欧美亚洲韩国日本不卡 | 特黄aa级毛片免费视频播放 | 欧美超高清xoxoxoxo | 国产精品视频久久久久 | 农村寡妇野外情一级毛片 |